SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing heightened attention following a major new contract award from the U.S. Space Force for satellite development, cementing its role as a vertically integrated space solutions provider. The community is actively discussing this significant win, alongside recent successful launches and the company's expanding capabilities beyond just launch services, positioning it strongly within a rapidly evolving space sector.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending as investors navigate a complex energy market, balancing ongoing geopolitical supply disruptions, such as attacks on Russian infrastructure and US sanctions, against concerns of a global oil surplus. Despite recent sideways price action, many in the community are actively accumulating, anticipating a significant breakout driven by long-term demand from the rapid expansion of AI and data centers, complemented by its attractive dividend yield.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing strong community discussion, primarily fueled by a recent institutional downgrade that has intensified debates about its high valuation and perceived underperformance compared to other semiconductor stocks. Despite this, many investors remain bullish, highlighting Arm's foundational role in AI infrastructure, power-efficient architecture, and strategic partnerships as key drivers for significant long-term growth in robotics and autonomous technologies.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is a focal point of discussion due to Ripple's expanded partnership with TJM Investments and ongoing anticipation of the Clarity Act, expected to provide essential regulatory guidance. The community is sharply divided, with proponents highlighting XRP's utility as a global liquidity bridge and its growing institutional adoption and ETF inflows, viewing current price levels as an accumulation opportunity for future tokenization of assets. Conversely, many express frustration over perceived price stagnation, attributing it to market manipulation and dismissing its long-term viability.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following multiple analyst upgrades, including new 'Buy' ratings and increased price targets, which are fueling bullish sentiment around its long-term potential. The company also announced an expanded $60 million partnership with QuantumBasel and a new collaboration to build a national quantum communication network in Slovakia, reinforcing its strategic positioning. While many in the community envision IonQ as a future leader in the quantum computing sector, discussions also touch on its current valuation and the broader nascent stage of the industry.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV) is attracting significant attention, with the community actively discussing strong technical indicators suggesting a "next leg" up after a period of consolidation. Enthusiasm is further fueled by mentions of buybacks and the Onchain Matrix treasury loop, alongside a specific report of Synthetix and Derive collaborating to build derivatives on Ethereum.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is generating buzz due to ongoing anticipation of its ISO 20022 compliance and recent strategic partnerships, positioning it to revolutionize real-time payments. While many in the community are bullish, accumulating and staking tokens for future growth, some express frustration over price stagnation and perceived market manipulation despite continuous positive developments. The network is actively building a compliant, multi-chain payment infrastructure aimed at widespread adoption.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as recent developments highlight its growing integration into traditional finance, with the European Central Bank piloting blockchain technology and JPMorgan launching a stablecoin on the network. Community sentiment is sharply divided, with many anticipating a significant rally fueled by these institutional moves and technical advancements in zkEVMs, while others voice concerns over perceived market manipulation and resistance around key price levels.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending after delivering strong earnings driven by record battery storage shipments and announcing a strategic move to consolidate U.S. manufacturing operations. The market is actively discussing the company's significant undervaluation relative to its assets and the substantial benefits expected from U.S. production credits, alongside speculation regarding a potential Recurrent Energy deal. Many see CSIQ as an emerging energy provider for AI data centers, contributing to a strong bullish sentiment and talks of a short squeeze.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is trending due to heightened geopolitical tensions impacting global oil prices, drawing significant community discussion on its potential upside. Traders are actively eyeing COP's strategic focus on low-cost production and expansion into key areas like LNG and Alaskan development. Recent analyst upgrades and substantial contract wins further fuel investor interest, alongside its attractive dividend.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>&nbsp;</li></ul>&nbsp;Shares of Altimmune, Inc. (ALT) jumped 16% in premarket trading on Friday after it reported positive topline results from its Phase 2b IMPACT trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).Pemvidutide is a drug that targets both GLP-1 and glucagon receptors and is used to treat liver diseases.The company said that the 48-week data showed statistically significant improvements versus placebo in key non-invasive liver tests, including enhanced liver fibrosis and liver stiffness, with continued progress from week 24. The higher dose also delivered additional weight loss without signs of plateauing, while maintaining a favorable safety profile.Altimmune said it held a productive End-of-Phase 2 meeting with the FDA, aligning on plans for a registrational Phase 3 trial."These results reinforce that pemvidutide may address both liver-specific and metabolic drivers of MASH without compromising tolerability – three critical elements of a potential effective treatment for this patient population,” said Mazen Noureddin, M.D., IMPACT trial principal investigator, Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board for Summit and Pinnacle Clinical Research.&nbsp;<a href="https://stocktwits.com/symbol/ALT">ALT</a> was the top-trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits shifted to 'bullish' from 'neutral' a day earlier.&nbsp;One user said proof that pemvidutide is an effective GLP1/Glucagon agonist continues to grow.<stembedurl>https://stocktwits.com/Independentquest/message/639732825</stembedurl>However, another user was bearish on the stock's price movement.<stembedurl>https://stocktwits.com/4Reel/message/639729717</stembedurl>Year-to-date, the stock has declined more than 40%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug

New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.

Why Is Altimmune Stock Up Over 10% Before The Bell?

Equity

Altimmune (NASDAQ:ALT) Stock Price Up 12.2% - Here's Why

Altimmune (NASDAQ:ALT) Stock Price Up 12.2% - Still a Buy...

Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?

The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT

Geode Capital Management LLC lifted its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 13.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission...

Altimmune (NASDAQ:ALT) Stock Price Down 6.6% - Time to Sell?

Altimmune (NASDAQ:ALT) Shares Down 6.6% - Here's What Happened...

Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT

Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...

Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...

Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

<ul class="summary-bullets"><li>Retail traders focused on AI-driven biopsy findings and clearer dose-response&nbsp;exuded increased confidence in pemvidutide’s potential.</li><li>Analysts remained divided, with&nbsp;some citing strong MASH resolution and safety, while skeptics questioned differentiation and funding needs.</li><li>Lancet publication and AASLD late-breaker added momentum as Altimmune advanced additional liver-disease programs toward 2026 readouts.</li></ul>Retail discussion around Altimmune intensified over the weekend as investors looked ahead to the 48-week readout from the company’s IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2025.&nbsp;<h2 class="st-heading-2">AI-Based Biopsy Analysis Adds Fresh Momentum</h2>Last week, Altimmune released results from an AI-based analysis of liver biopsies from the IMPACT Phase 2b trial. The company reported that 31% of patients in the 1.8 mg pemvidutide arm and 12% in the 1.2 mg arm achieved a 60% reduction in total fibrosis, compared with 8% for placebo. Improvements were also observed in early and advanced fibrosis categories, with reductions in the area of fibrosis exceeding 60% in select patient groups compared with placebo.Following the analysis, Citizens JMP lowered its price target to $14 and maintained an ‘Outperform’ rating,&nbsp;noting that&nbsp;it looked ahead to the late-breaking oral presentation at the Liver Meeting and the 48-week dataset expected this quarter. UBS maintained a ‘Buy’ rating, while Jefferies reiterated its ‘Buy’ recommendation, viewing pemvidutide as viable after meeting key histology endpoints at 24 weeks.<h2 class="st-heading-2">Mixed MASH Readout In July Still Shapes Sentiment</h2>Altimmune’s June and July update on its 24-week IMPACT&nbsp;Phase 2b results set the tone for the stock this year.&nbsp;The company reported that up to 59.1% of patients on pemvidutide achieved MASH resolution without worsening of fibrosis, compared to 19.1% for the placebo group. However, the endpoint of fibrosis improvement without worsening of MASH did not reach statistical significance.Despite this, the trial showed reductions in liver fat, inflammation and biomarkers of fibrosis, alongside meaningful weight loss, with up to 6.2% loss in treated patients compared with 1.0% for placebo. Safety remained favorable, with extremely low discontinuations and no drug-related serious adverse events.<h2 class="st-heading-2">Analyst Community Diverges Across The Year</h2>Bullish analysts’ optimism hinged on the drug’s early MASH resolution signal, weight loss trajectory and tolerability. UBS, Stifel, Jefferies and H.C. Wainwright all maintained ‘Buy’ ratings at various points, describing the 24-week results as either differentiated, fast-acting, viable for Phase 3 advancement or supportive of a potential best-in-class profile. Several of these firms highlighted AI-assisted fibrosis reads and non-invasive tests as consistent with anti-fibrotic activity.Others expressed more skepticism. In October, Citizens JMP cut its target earlier, while still keeping an ‘Outperform’ rating. Goldman Sachs resumed coverage with a ‘Sell’ rating, citing a lack of meaningful differentiation in obesity and MASH. Concerns about the company’s ability to fund a full Phase 3 program, especially after the mixed fibrosis outcome, were noted among analysts.<h2 class="st-heading-2">Peer-Reviewed Boost</h2>Last week, Altimmune said that The Lancet had published the 24-week efficacy and safety data from the IMPACT Phase 2b trial. The data were also selected for a late-breaking oral presentation at The Liver Meeting 2025 hosted by AASLD. Investigators highlighted significant MASH resolution, reductions in liver fat, anti-fibrotic signals and weight loss, reinforcing the drug’s potential to treat patients with moderate to advanced fibrosis.<h2 class="st-heading-2">Stocktwits Users See No ‘Breaks’ Ahead</h2>On Stocktwits, retail sentiment for Altimmune was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/139;" src="https://news.stocktwits-cdn.com/alt_ss_jpg_da81507313.webp" alt="alt ss.jpg" width="972" height="139"><figcaption>ALT sentiment and message volume as of November 16 | Source: Stocktwits</figcaption></figure>One user discussing the upcoming 48-week dataset pointed to the latest AASLD-published fibrosis odds-ratio findings and the clearer dose-response signals seen in the PathAI-derived analysis, suggesting these results strengthen the case for exploring a higher 2.4 mg dose aimed at accelerating fibrosis reduction, while keeping 1.8 mg and 1.2 mg positioned for broader cardiometabolic use and long-term maintenance.<stembedurl>https://stocktwits.com/BTECHINV/message/636410473</stembedurl>Another user said, “If 48 week MASH data is ‘BEST IN CLASS’ like the weight loss/muscle sparring data, we should get at least $15B for both…not to mention the other indications.”<stembedurl>https://stocktwits.com/Lazarus2024/message/636408646</stembedurl>A third user said, “48 week should confirm fibrosis improvement and we should race to 2 billion MC on it FAST. no breaks once it’s out.”<stembedurl>https://stocktwits.com/SuperPuncher/message/636408207</stembedurl><a href="https://stocktwits.com/symbol/ALT">Altimmune’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.25	--	--	N/A
Q3 '25	-$0.27	-$0.21	22.83%	BEAT
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT
Q4 '24	-$0.33	-$0.33	0.75%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALT News

ALTAltimmune Inc